- Home
- GNTA vs UNCY Comparison
GNTA vs UNCY Comparison
Compare GNTA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- UNCY
- Stock Information
- Founded
- GNTA 2014
- UNCY 2016
- Country
- GNTA Italy
- UNCY United States
- Employees
- GNTA N/A
- UNCY N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- UNCY Health Care
- Exchange
- GNTA Nasdaq
- UNCY Nasdaq
- Market Cap
- GNTA 70.8M
- UNCY 71.8M
- IPO Year
- GNTA 2021
- UNCY 2021
- Fundamental
- Price
- GNTA $4.22
- UNCY $0.62
- Analyst Decision
- GNTA Strong Buy
- UNCY Strong Buy
- Analyst Count
- GNTA 1
- UNCY 3
- Target Price
- GNTA $25.00
- UNCY $5.50
- AVG Volume (30 Days)
- GNTA 6.9K
- UNCY 510.7K
- Earning Date
- GNTA 01-01-0001
- UNCY 05-16-2025
- Dividend Yield
- GNTA N/A
- UNCY N/A
- EPS Growth
- GNTA N/A
- UNCY N/A
- EPS
- GNTA N/A
- UNCY N/A
- Revenue
- GNTA N/A
- UNCY N/A
- Revenue This Year
- GNTA N/A
- UNCY N/A
- Revenue Next Year
- GNTA N/A
- UNCY $1,502.84
- P/E Ratio
- GNTA N/A
- UNCY N/A
- Revenue Growth
- GNTA N/A
- UNCY N/A
- 52 Week Low
- GNTA $2.79
- UNCY $0.20
- 52 Week High
- GNTA $7.28
- UNCY $1.16
- Technical
- Relative Strength Index (RSI)
- GNTA 59.59
- UNCY 51.83
- Support Level
- GNTA $3.84
- UNCY $0.59
- Resistance Level
- GNTA $4.25
- UNCY $0.66
- Average True Range (ATR)
- GNTA 0.25
- UNCY 0.03
- MACD
- GNTA 0.04
- UNCY -0.00
- Stochastic Oscillator
- GNTA 95.95
- UNCY 40.05
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.